帕金森病嗅觉障碍的研究进展

doi:10.16352/j.issn.1001-6325.2023.06.0994

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 994-997.doi: 10.16352/j.issn.1001-6325.2023.06.0994

帕金森病嗅觉障碍的研究进展

任鹏, 陈雅丽, 张娴文^*

昆明理工大学医学院, 云南昆明 650500

收稿日期:2022-03-28 修回日期:2022-07-21 出版日期:2023-06-05 发布日期:2023-05-31
通讯作者: ^*xianwen-zhang0717@163.com
基金资助:
国家自然科学基金(81901118)

Olfactory disorder in Parkinson's disease

REN Peng, CHEN Yali, ZHANG Xianwen^*

Medical College, Kunming University of Science and Technology, Kunming 650500, China

Received:2022-03-28 Revised:2022-07-21 Online:2023-06-05 Published:2023-05-31
Contact: ^*xianwen-zhang0717@163.com

摘要/Abstract

摘要： 嗅觉障碍是帕金森病(PD)最常见和最具特征的早期非运动症状,可作为PD诊断的重要依据之一。PD嗅觉障碍的机制非常复杂,是基础和临床研究的难点。病理性α-突触核蛋白的聚集,多巴胺(DA)、乙酰胆碱(ACh)、五羟色胺(5-HT)和炎性反应等神经介质的改变与PD嗅觉障碍的发生密切相关。深入研究PD嗅觉障碍的发病机制,可为治疗提供新思路及新靶点。

关键词: 帕金森病, 嗅觉障碍, α-突触核蛋白, 炎性反应, 神经递质

Abstract: Olfactory dysfunction is the most common early non-motor symptom of Parkinson's disease (PD), which is used as a marker for the diagnosis of PD. The mechanism of olfactory dysfunction is very complex, which is a challenge in the research. The neuromediator such as the accumulation of α-synuclein, dopamine (DA), acetylcholine (ACh), 5-hydroxytryptamine (5-HT) and inflammatory factors are implicated in the olfactory dysfunction in PD. To further study the mechanism of olfactory dysfunction in PD may provide new ideas and therapeutic targets for treatment.

Key words: Parkinson's disease, olfactory dysfunction, α-synuclein, inflammation response, neuromediator

中图分类号:

R730.2

任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展[J]. 基础医学与临床, 2023, 43(6): 994-997.

REN Peng, CHEN Yali, ZHANG Xianwen. Olfactory disorder in Parkinson's disease[J]. Basic & Clinical Medicine, 2023, 43(6): 994-997.

参考文献 25

[1]	Roos DS, Klein M, Deeg DJH, et al. Prevalence of prodromal symptoms of Parkinson's disease in the late middle-aged population[J]. J Parkinsons Dis, 2022,12:967-974.
[2]	Nabizadeh F, Pirahesh K, Khalili E. Olfactory dysfunc-tion is associated with motor function only in tremor-dominant Parkinson's disease[J]. Neurol Sci, 2022,2:1-9.
[3]	Solla P, Masala C, Liscia A, et al. Sex-related differ-ences in olfactory function and evaluation of possible confounding factors among patients with Parkinson's disease[J]. J Neurol, 2020,267:57-63.
[4]	Lee YH, Bak Y, Park CH, et al. Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia[J]. Neurobiol Aging, 2020,89:63-70.
[5]	Marrero-Gonzalez P, Iranzo A, Bedoya D, et al. Prodro-mal Parkinson disease in patients with idiopathic hyposmia[J]. J Neurol, 2020,267:3673-3682.
[6]	Zhou Y, He R, Zhao Y, et al. Olfactory dysfunction and its relationship with clinical features of Parkinson's disease[J]. Front Neurol, 2020,11:1-9.
[7]	Glover A, Pillai L, Dhall R, et al. Olfactory deficits in the freezing of gait phenotype of Parkinson's disease[J]. Front Neurol, 2021,12:1-9.
[8]	Roh H, Kang J, Koh SB, et al. Hippocampal volume is related to olfactory impairment in Parkinson's disease[J]. J Neuroimaging, 2021,31:1176-1183.
[9]	Lin CY, Chang TY, Chang MH. Dysosmia Is a predictor of motor function and quality of life in patients with Parkinson's disease[J]. J Pers Med, 2022,12:1-13.
[10]	Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson's disease[J]. Neuropathology, 2020,40:415-425.
[11]	Uemura N, Ueda J, Yoshihara T, et al. alpha-synuclein spread from olfactory bulb causes hyposmia, anxiety, and memory loss in BAC-SNCA mice[J]. Mov Disord, 2021,36:2036-2047.
[12]	Li R, Lu Y, Zhang Q, et al. Piperine promotes autophagy flux by P2RX4 activation in SNCA/alpha-synuclein-induced Parkinson disease model[J]. Autophagy, 2022,18:559-575.
[13]	Kulkarni AS, Del Mar Cortijo M, Roberts ER, et al. Perturbation of in vivo neural activity following alpha-synuclein seeding in the olfactory bulb[J]. J Parkinsons Dis, 2020,10:1411-1427.
[14]	Pass T, Assfalg M, Tolve M, et al. The impact of mitochondrial dysfunction on dopaminergic neurons in the olfactory bulb and odor detection[J]. Mol Neurobiol, 2020,57:3646-3657.
[15]	Ma K, Han C, Zhang G, et al. Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease[J]. Biochem Biophys Res Commun, 2019,513:306-312.
[16]	Zhang W, Sun C, Shao Y, et al. Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb[J]. Sci Rep, 2019,9:254-267.
[17]	Jiang S, Berger S, Hu Y, et al. Alterations of the motor and olfactory functions related to Parkinson's disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons[J]. Front Neurosci, 2020,14:356-367.
[18]	Oh E, Park J, Youn J, et al. Olfactory dysfunction in early Parkinson's disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction[J]. Clin Neurophysiol, 2017,128:1061-1068.
[19]	Yang J, Lv DJ, Li LX, et al. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease[J]. Neurotoxicology, 2019,73:175-182.
[20]	Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson's disease[J]. Neurosci Bull, 2017,33:515-525.
[21]	Morais LH, Hara DB, Bicca MA, et al. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease[J]. Behav Pharmacol, 2018,29:199-210.
[22]	Cui C, Hong H, Shi Y, et al. Vancomycin pretreatment on MPTP-Induced Parkinson's disease mice exerts neuroprotection by suppressing inflammation both in brain and gut[J]. J Neuroimmune Pharmacol, 2022,1:1-18.
[23]	Niu H, Wang Q, Zhao W, et al. IL-1beta/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-synuclein pathology in the olfactory bulb, substantia nigra and striatum[J]. Brain Pathol, 2020,30:1102-1118.
[24]	Zhang X, Huang W, Shao Q, et al. Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model[J]. Toxicol Lett, 2020,325:1-13.
[25]	Chen Y, Zhang QS, Shao QH, et al. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP[J]. Acta Pharmacol Sin, 2019,40:991-998.

帕金森病嗅觉障碍的研究进展

Olfactory disorder in Parkinson's disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高源, 郑刚, 齐靖, 张凤. NLRP3炎性小体在心脏病发病中的作用研究进展[J]. 基础医学与临床, 2023, 43(7): 1162-1166.
[2]	季玮, 朱玥, 尧惠慈, 卢红艳. 白三烯C4及2型固有淋巴细胞在支气管肺发育不良中的变化及意义[J]. 基础医学与临床, 2023, 43(5): 711-716.
[3]	雷星煜, 冯雪松, 晁旭. 11β-HSD1在炎性反应、肝癌的发生发展与免疫中作用的研究进展[J]. 基础医学与临床, 2023, 43(5): 837-841.
[4]	孙莹, 杨治安, 何瑶, 余勤. HMGB1信号通路在支气管哮喘中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 690-694.
[5]	李立亚, 秦霈. 星形胶质细胞在中枢神经系统炎性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 665-668.
[6]	蒋烨, 余卓颖, 李民. 炎性反应在糖尿病神经病变发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 669-673.
[7]	刘芬, 胡润芳, 茅松, 徐敏, 石文静, 陈凌. 地塞米松减轻过敏性哮喘模型小鼠气道炎性反应[J]. 基础医学与临床, 2023, 43(3): 402-407.
[8]	秦玉春, 邝向东, 蔡林再, 谢景臣, 陈山. 双氢青蒿素减轻慢性阻塞性肺疾病(COPD)模型大鼠肺损伤[J]. 基础医学与临床, 2023, 43(3): 427-432.
[9]	岳静静, 伍超, 高歌, 鲁玲玲. α-突触核蛋白/A53T突变体损伤SH-SY5Y细胞的MAM并导致线粒体结构异常及自噬[J]. 基础医学与临床, 2023, 43(2): 219-224.
[10]	付士祥, 席月, 丁龙坤, 闫曼, 赵俊, 焦玉东, 吴亮. 鲍曼不动杆菌外膜囊泡诱发人单核-巨噬细胞THP-1的炎性反应[J]. 基础医学与临床, 2023, 43(1): 110-115.
[11]	曾颖, 付桂莉. 黄芩提取物抑制IL-22诱导的人角质形成细胞系HaCaT过度增殖[J]. 基础医学与临床, 2023, 43(1): 123-129.
[12]	杨广林, 任丽娟, 陈文静, 熊维军. LncRNA MINCR靶向miR-223抑制LPS诱导的人肺泡上皮细胞系A549损伤和炎性反应[J]. 基础医学与临床, 2023, 43(1): 102-109.
[13]	顾炜, 祝剑平, 吴品雯. 丙泊酚减轻低氧诱导的大鼠肾上腺嗜铬细胞瘤细胞系PC12炎性反应和细胞凋亡[J]. 基础医学与临床, 2023, 43(1): 137-143.
[14]	黄华, 周龙, 姚迪, 许诣. LncRNA PVT1 通过调节miR-214/STAT6 轴减轻哮喘模型小鼠气道炎性反应[J]. 基础医学与临床, 2022, 42(9): 1374-1380.
[15]	谷文浩, 郭飞霞, 徐宇鹏, 陆馨雨, 胡青青. 淫羊藿苷改善重症急性胰腺炎模型大鼠肺损伤[J]. 基础医学与临床, 2022, 42(9): 1400-1405.